113 related articles for article (PubMed ID: 32683791)
1. Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2.
Ma WL; Chou CH; Chen JP; Kuo SH
Dermatol Ther; 2020 Nov; 33(6):e14035. PubMed ID: 32683791
[TBL] [Abstract][Full Text] [Related]
2. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.
Falchook GS; Leidner R; Stankevich E; Piening B; Bifulco C; Lowy I; Fury MG
J Immunother Cancer; 2016; 4():70. PubMed ID: 27879972
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
[TBL] [Abstract][Full Text] [Related]
4. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab.
Venkatesh S; Al-Haseni A; Sahni D
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31377718
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.
Kacew AJ; Harris EJ; Lorch JH; Haddad RI; Chau NG; Rabinowits G; LeBoeuf NR; Schmults CD; Thakuria M; MacConaill LE; Hanna GJ
Eur J Cancer; 2019 May; 113():1-9. PubMed ID: 30954880
[TBL] [Abstract][Full Text] [Related]
6. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
Maubec E; Boubaya M; Petrow P; Beylot-Barry M; Basset-Seguin N; Deschamps L; Grob JJ; Dréno B; Scheer-Senyarich I; Bloch-Queyrat C; Leccia MT; Stefan A; Saiag P; Grange F; Meyer N; de Quatrebarbes J; Dinulescu M; Legoupil D; Machet L; Dereure O; Zehou O; Montaudié H; Wierzbicka-Hainaut E; Le Corre Y; Mansard S; Guégan S; Arnault JP; Dalac S; Aubin F; Alloux C; Lopez I; Cherbal S; Tibi A; Lévy V;
J Clin Oncol; 2020 Sep; 38(26):3051-3061. PubMed ID: 32730186
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases.
Blum V; Müller B; Hofer S; Pardo E; Zeidler K; Diebold J; Strobel K; Brand C; Aebi S; Gautschi O
Eur J Dermatol; 2018 Feb; 28(1):78-81. PubMed ID: 29336323
[TBL] [Abstract][Full Text] [Related]
9. Anti PD-1 Checkpoint Inhibitor As a First-Line Treatment for Advanced Cutaneous Squamous Cell Carcinoma.
Bopota K; Donnelly O; Borumandi F
J Craniofac Surg; 2023 May; 34(3):e247-e249. PubMed ID: 36441840
[TBL] [Abstract][Full Text] [Related]
10. Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation.
Zhang Q; Li Y; Zhang Y; Deng Z; Ding Y
World J Surg Oncol; 2024 Feb; 22(1):50. PubMed ID: 38336701
[TBL] [Abstract][Full Text] [Related]
11. Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome.
Khaddour K; Musiek A; Cornelius LA; Dehdashti F; Westervelt P; Fields R; Ansstas G
J Immunother Cancer; 2019 Dec; 7(1):338. PubMed ID: 31801591
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma.
Patel R; Chang ALS
Am J Clin Dermatol; 2019 Aug; 20(4):477-482. PubMed ID: 30737731
[TBL] [Abstract][Full Text] [Related]
13. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
Benzaquen M
Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
[TBL] [Abstract][Full Text] [Related]
14. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Hernández-Guerrero T; Doger B; Moreno V
Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
[TBL] [Abstract][Full Text] [Related]
15. PD-1 Blockade With Concurrent Radiotherapy for Locally Advanced Inoperable Cutaneous Squamous Cell Carcinoma.
Joseph K; Walker J; Raziee H; Faruqi S; Smylie M
J Cutan Med Surg; 2022; 26(3):243-248. PubMed ID: 34866423
[TBL] [Abstract][Full Text] [Related]
16. First-line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD-L1: A case report.
Hamai K; Tanahashi H; Ueno S; Konishi H; Matsumura M; Nomura A; Nakamoto K; Isoyama S; Tanimoto T; Shoda H; Ishikawa N
Thorac Cancer; 2020 Jun; 11(6):1716-1719. PubMed ID: 32291904
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab-radiotherapy combination in the management of locally advanced cutaneous squamous cell carcinoma.
Joseph K; Alkaabi K; Warkentin H; Ghosh S; Jha N; Smylie M; Walker J
J Med Imaging Radiat Oncol; 2019 Apr; 63(2):257-263. PubMed ID: 30549229
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.
Salzmann M; Leiter U; Loquai C; Zimmer L; Ugurel S; Gutzmer R; Thoms KM; Enk AH; Hassel JC
Eur J Cancer; 2020 Oct; 138():125-132. PubMed ID: 32882466
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of RAS Mutations and P53 Expression in Cutaneous Squamous Cell Carcinomas.
Campos MA; Macedo S; Fernandes MS; Pestana A; Pardal J; Batista R; Vinagre J; Sanches A; Baptista A; Lopes JM; Soares P
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32640663
[No Abstract] [Full Text] [Related]
[Next] [New Search]
